Jul 03, 2026
Summary In the US, chronic low back pain affects about 28% of the population, and DDD is estimated to account for roughly half of specific CLBP cases, or around 14 million diagnosed prevalent cases in 2025. Standard care includes pain relief, NSAIDs, physical therapy, lifestyle changes, injections, and surge...
Read More...
Feb 16, 2026
What is Chronic Lower Back Pain Chronic lower back pain (CLBP) is a debilitating musculoskeletal condition that affects hundreds of millions of people worldwide, characterized by persistent pain lasting 12 weeks or longer. Despite significant advancements in orthopedic surgery and pain management, CLBP remains a...
Read More...
Sep 21, 2023
Zepp Health Launched a New Line of OTC Hearing Aids for its Zepp Clarity Brand On September 19, 2023, Zepp Clarity, a smart hearing solutions brand owned by Zepp Health, a health technology company, announced the launch of Zepp Clarity Pixie, a next-generation premium hearing solution. The Pixie, which ...
Read More...
Mar 12, 2021
More than 100 million people are living with one or the other form of Chronic Pain in the USA, says the Institute of Medicine. The available treatments to tackle cancer, as well as non-cancer pain, include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, or combinations of opioids and non-narc...
Read More...
Jul 03, 2019
Chronic Lower Back Pain (CLBP) market size in 7MM is expected to grow at a CAGR of 4.84% for the study period (2017-2028). The CLBP therapy market although, is entirely dependent on supportive therapies, but the drugs such as opioids and NSAIDs, have also been approved to ease the pain associated with CLBP. The pre...
Read More...
Jul 01, 2019
Each year, approximately 3.6 million people in the United States complain of Lower back pain (LBP). Among all types of chronic pain, back pain has often been suggested to be the most frequent type and is considered the second most common neurologic disease and most physician visits can be attributed to it. The lowe...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
Newsletter/Whitepaper